These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 29129559)
1. Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Kayhanian H; Goode E; Sclafani F; Ang JE; Gerlinger M; Gonzalez de Castro D; Shepherd S; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N Clin Colorectal Cancer; 2018 Mar; 17(1):e69-e76. PubMed ID: 29129559 [TBL] [Abstract][Full Text] [Related]
2. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status. Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
5. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Karthaus M; Hofheinz RD; Mineur L; Letocha H; Greil R; Thaler J; Fernebro E; Oliner KS; Boedigheimer M; Twomey B; Zhang Y; Demonty G; Köhne CH Br J Cancer; 2016 Nov; 115(10):1215-1222. PubMed ID: 27764839 [TBL] [Abstract][Full Text] [Related]
6. BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? Price TJ; Beeke C; Townsend AR; Lo L; Amitesh R; Padbury R; Roder D; Maddern G; Moore J; Karapetis C Mol Diagn Ther; 2016 Feb; 20(1):75-82. PubMed ID: 26714964 [TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499 [TBL] [Abstract][Full Text] [Related]
8. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278 [TBL] [Abstract][Full Text] [Related]
10. Impact of Metastasectomy in the Multimodality Approach for Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173 [TBL] [Abstract][Full Text] [Related]
12. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M; BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148 [TBL] [Abstract][Full Text] [Related]
13. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
14. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). Kurreck A; Geissler M; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Stintzing S; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Modest DP J Cancer Res Clin Oncol; 2020 Oct; 146(10):2681-2691. PubMed ID: 32449003 [TBL] [Abstract][Full Text] [Related]
15. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563 [TBL] [Abstract][Full Text] [Related]
16. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]
17. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
18. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339 [TBL] [Abstract][Full Text] [Related]
19. Real-world first-line treatment of patients with BRAF Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253 [TBL] [Abstract][Full Text] [Related]
20. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]